Abstract 5262
Background
ICI is a standard of care in R/M HNSCC pts progressing to platinum compounds. However, few pts respond to ICI and irAEs could limit their use.There are contradictory reports regarding the association of irAEs and outcomes to ICI. The aim of this study is to further evaluate the potential impact of irAEs on outcomes for HNSCC.
Methods
We performed a retrospective observational study based on all R/M HNSCC pts treated by ICI in our center during 2014-19. To limit the bias due to the association between ICI administration duration, obtention of objective response (OR) and occurrence of irAE, a Landmark analysis method with 90 days (d) cut-off was used.
Results
We included 103 R/M HNSCC pts (80% male, 73% smokers). Primary tumor locations were: oropharynx (42%), oral cavity (23%), hypopharynx (18%) and larynx (17%). ICI were administered as monotherapy (43%) or combination (57%; CTLA-4 inhibitor, ICOS agonist). There were 14 responders (R) with median time to obtain OR of 102 d (8 after 90 d). Median ICI duration was 376 d in R pts and 84 d in others. irAEs were observed in 38 pts (37%), with low frequency of grade (G) 3-4 (6%). Occurrence of irAEs within the first 90 d (named early AEs) was observed in 25 pts (24%). 51 pts (50%) remained on ICI beyond 90 d, including all the 14 R: 30 pts (59%) had irAEs and 17 (33%) had early irAEs. In total cohort, OR was more frequent in pts with any irAE (32%) than in others (3%). Results were similar with irAE G2-4: 42% OR vs 5% OR. But, using landmark method, in pts who received ≥ 90 d ICI, this association was no longer observed: 35% of pts with early irAEs had OR vs 24% in other pts (p = 0.37), and 36% vs 25% for early irAEs of G2-4 (p = 0.47). Median [95%CI] PFS and OS were 3.6 months (m) [2.9-4.5] and 10.6m [7.6-13.2] in total cohort; 5.8 m [4.8-7.7] and 19.1 m [12.6-32.5] in ICI ≥90 d. Early irAEs were not associated with PFS or OS in this latter subgroup.
Conclusions
The impact of irAEs on outcomes could be mistaken if not taking into consideration the ICI duration because the likelihood of irAEs and OR increases with treatment duration. Using a Landmark analysis with 90 d cut-off, we did not observe an association between irAEs and outcome in R/M HNSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
N. Baste Rotllan: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol Meyers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Nanobiotix; Honoraria (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (institution): PharmaMar. All other authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract